#federal funding

Advocates push for increased federal cancer research funding among list of essential cancer priorities

Gavin Ha explains his research on liquid biopsies—blood samples with traces of DNA that provide molecular details about cancer.

Biden may not have used the right word when he described the pandemic as “over,” but things are trending in the right direction.

After mishandling COVID-19 and monkeypox, the Centers for Disease Control and Prevention aims to change—with help from Mary Wakefield.

“We urge the Senate and House to consider the nation’s…research and prevention needs and allocate maximum medical research funding.”

The court sided with the hospitals, which challenged a $1.6 billion Trump-era cut to 340B Medicare reimbursements.

Investments will boost Biden’s priority of ending cancer as we know it as part of the Cancer Moonshot and his Unity Agenda for the nation.

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

Biden extends the health insurance enrollment period, while his COVID-19 stimulus plan makes massive changes to the Affordable Care Act.

The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.

I wanted to highlight the eye-popping discrepancy in how our federal research dollars are allocated for lung cancer.

The NCI stands to lose nearly $900 million, but childhood cancer would see an increase.

Barack Obama proposed $1 billion for the Cancer Moonshot; George W. Bush asked for $15 billion to end the global HIV/AIDS epidemic.

Four out of 10 FDA workers are sidelined.

This is, without a doubt, a time of great hope in cancer research.

More than 300 organizations call for more funding for the National Institutes of Health.